by Osel | Jan 23, 2018 | announcements, Featured, LACTIN-V, MUCOCEPT
It’s the most common vaginal infection you’ve probably never heard of: Bacterial vaginosis (BV). It’s the culprit that causes embarrassing odors and discharge, and the reason many women visit their gynecologist. Nearly one-third of U.S. women of reproductive age have...
by Osel | Jan 17, 2018 | announcements
LACTIN-V Enters Clinical Study to Improve the Success Rate of IVF in Women with Imbalanced Vaginal Microbiomes Study based on findings that women with abnormal vaginal microbiota had only 9% success of pregnancy with IVF versus 44% for those with healthy vaginal...
by Osel | Jan 19, 2017 | announcements, Featured
Osel was featured in a recent article in Nature Medicine, “Living therapeutics: Scientist genetically modify bacteria to deliver drugs,” by Amy Maxmen. The article profiles our Director of Research Laurel Lagenaur and her work at Osel to investigate ways...
by Osel | Oct 10, 2016 | announcements
Osel Featured in Chemistry & Industry Magazine Osel was featured in the September issue of Chemistry & Industry Magazine, a publication of the UK Society of Chemical Industry (SCI), for an article focusing on the role of the healthy vaginal microbiome in...
by Osel | Jul 21, 2016 | announcements
Osel, Inc. Comments on New Study Showing Role of Vaginal Microbiome in Women’s Health Osel’s Live Biotherapeutic Approach Aims to Restore Healthy Microbial Balance in Women Affected by Vaginal Dysbiosis Company Currently Conducting Phase 2b Clinical Trial of Lead...
by Osel | May 16, 2016 | announcements
Osel, Inc.’s Lead Product LACTIN-V Enters Phase 2b Study to Prevent Recurrence of Bacterial Vaginosis Mountain View, CA (May 11, 2016): Osel, Inc. today announced the initiation of a Phase 2b clinical study of its lead product candidate, LACTIN-V, to prevent the...
